Publikationen

  • Zimbelmann F, Flaute S, Deipenbrock M, Ahlke E, Hempel G, Baumann-Köhler M. . „Anwendung stark wirksamer retardierter Opioide in der Pädiatrie : Fallstricke und Lösungen für Morphin und Hydromorphon.“ Schmerz 204. doi: 10.1007/s00482-023-00775-w.
  • Opitz P, Fobker M, Fabian J, Hempel G. . ‘Development and validation of a bioanalytical method for the quantification of methotrexate from serum and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.’ Journal of Chromatographic Science 1715: 464610. doi: 10.1016/j.chroma.2023.464610.
  • Ramadan, O.[1]; Opitz, P.[2, 3]; Hempel, G. [4]. . ‘Development and Validation of a High-Performance Liquid Chromatography With Ultraviolet Detection Method to Facilitate Therapeutic Monitoring of Teicoplanin Using Dried Blood Spots.’ Therapeutic Drug Monitoring 00: 1–7. doi: 10.1097/FTD.0000000000001202.

  • Schatz, LM; Brinkmann, A; Röhr, A; Frey, O; Greppmair, S; Weinelt, F; Zoller, M; Scharf, C; Hempel, G; Liebchen, U. . ‘Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.’ Antimicrobial Agents and Chemotherapy 1. doi: 10.1128/aac.00104-23.
  • Rosser SPA, McLachlan AJ, Hempel G, Chung J, Shaw PJ, Keogh SJ, Nath CE. . ‘Validation of a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of N,N-dimethylacetamide and N-monomethylacetamide in pediatric plasma.’ Journal of Separation Science 46, Nr. 10. doi: 10.1002/jssc.202201003.
  • Ramadan O, Schatz LM, van den Heuvel I, Masjosthusmann K, Groll AH, Hempel G. . ‘Developing a Method for Quantifying Meropenem in Children-Volumetric Adsorptive Microsampling Versus Plasma Sampling.’ Therapeutic Drug Monitoring 45, Nr. 5: 623–630.
  • Gastine, SE; Rauwolf, KK; Pieper, S; Hempel, G; Lehrnbecher, T; Tragiannidis, A; Groll, AH. . ‘Voriconazole plasma concentrations and dosing in paediatric patients below 24 months of age.’ Mycoses 66, Nr. 11: 969–976.
  • Maierhöfer S, Waltering I, Würthwein G, Jacobs M, Hempel G. „Ein klinisches Entscheidungsunterstützungssystem für Medikationsanalysen in öffentlichen Apotheken: patientenberichtete Endpunkte der OPtiMed-Studie.“ präsentiert auf der Annual Meeting of the German Society of Clinical Pharmacy – DGKPha, Münster, .
  • Opitz, P; Zimmermann, S; Stapf, M; Klima, F; Müller, L; Fuxius, S; Illerhaus, G;Scherf-Clavel, O; Kloft, C; Hempel, G. „Erweiterung einer bioanalytischen Methode für das therapeutische Drug Monitoring von Axitinib in Plasma und Kapillarblut zu einer generischen Methode für orale Onkologika.“ präsentiert auf der Jahrestagung der Deutschen Gesellschaft für Klinische Pharmazie DGKPha, Münster, .

  • Khalil A, Würthwein G, Golitsch J, Hempel G, Fobker M, Gerss J, Möricke A, Zimmermann M, Smisek P, Zucchetti M, Nath C, Attarbaschi A, Von Stackelberg A, Gökbuget N, Rizzari C, Conter V, Schrappe M, Boos J, Lanvers-Kaminsky C. . ‘Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.’ Haematologica 107, Nr. 1. doi: 10.3324/haematol.2020.258525.
  • Bognàr T, Bartelink IH, Egberts T, Rademaker C, Versluys B, Slatter MA, Kletzel M, Nath CE, Cuvelier GDE, Savic RM, Dvorak C, Long-Boyle JR, Cowan MJ, Bittencourt H, Bredius M, Güngör T, Shaw PJ, Ansari M, Hassan M, Krajinovic M, Hempel G, Marktel S, Chiesa R, Théoret Y, Lund T, Orchard PJ, Wynn RRF, Boelens J, Lalmohamed A. . ‘Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation.’ Cellular Therapy and Transplantation 22. doi: 10.1016/j.jtct.2022.01.013.
  • Khalil, A; Würthwein, G; Golitsch, J; Hempel, G; Fobker, M; Gerss, J; Möricke, A; Zimmermann, M; Smisek, P; Zucchetti, M; Nath, C; Attarbaschi, A; Von Stackelberg, A; Gökbuget, N; Rizzari, C; Conter, V; Schrappe, M; Boos, J; Lanvers-Kaminsky, C. . ‘Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.’ Haematologica 107, Nr. 1: 49–57. doi: 10.3324/haematol.2020.258525.
  • Opitz, Patrick; Zimmermann, Sebastian; Mc Laughlin, M. Anna; Müller, Lothar; Fuxius, Stefan; Illerhaus, Gerald; Scherf-Clavel, Oliver; Kloft, Charlotte; Hempel, Georg. . ‘Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.’ Journal of Pharmaceutical and Biomedical Analysis 221: 115033. doi: 10.1016/j.jpba.2022.115033.
  • Lea Marie Schatz, Georg Hempel, Ferdinand Anton Weinelt, Uwe Liebchen. „Systematic evaluation of meropenem pharmacokinetic models for Bayesian forecasting in critically ill patients undergoing continuous renal replacement therapy.“ contributed to the Quantitative Systems Pharmacology Conference 2022, Leiden, .
  • Schatz, Lea Marie; Wicha, Sebastian G.; Hempel, Georg; de Hoog, Matthijs; Allegaert, Karel; Knibbe, CatherijneA.J; Völler, Swantje. „Model-informed precision dosing for vancomycin in children between 28 days and 18 years: Does the use of a multi-model approach improve the predictive performance?“ contributed to the Population Approach Group Europe 2022 (PAGE), Ljubljana, .
  • Hirn-Derksen B. ; Ryu C. ; Hyunki C. ; Kim J. Y. ; Hempel G. „Development of a pharmacokinetic model to predict disposition of Dutasteride in zebrafish embryos.“ contributed to the Population Approach Group Europe 2022 (PAGE), Ljubljana, .
  • Shahhossini, Morwarid; Lehmann, Florian; Schmidt, Christina; Arnemann, Philip-Helge; Kaiser, Luca Elisa; Ertmer, Christian; Hempel, Georg; Hessler, Michael. „Plasmakonzentration von Vancomycin nach Hämadsorption mit Cytosorb®.“ präsentiert auf der Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI), Hamburg, .
  • Shahhossini. Morwarid; Hessler, Michael; Hempel, Georg. „Development of a physiologically based pharmacokinetic model of Ciprofloxacin in ovine septic shock.“ contributed to the Population Approach Group Europe 2022 (PAGE), Ljubljana, .
  • Mohamed, Fakry F.; Anhlan, Darisuren; Schöfbänker, Michael; Schreiber, André; Classen, Nica; Hensel, Andreas; Hempel, Georg; Scholz, Wolfgang; Kühn, Joachim; Hrincius, Eike R., Stephan Ludwig. . ‘Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2.’ Pharmaceuticals 15, Nr. 5. doi: DOI: 10.3390/ph15050530.
  • Maierhöfer, S; Waltering, I; Jacobs, M; Würthwein, G; Appelrath, M; Koling, S; Hempel, G. . ‘Decision support software-guided medication reviews in elderly patients with polypharmacy: a prospective analysis of routine data from community pharmacies (OPtiMed study protocol).’ Journal of Pharmaceutical Policy and Practice 15, Nr. 1. doi: doi: 10.1186/s40545-022-00495-z.
  • Maierhöfer, S; Waltering, I; Jacobs, M; Appelrath, M; Hempel, G. . ‘Developing a questionnaire comprising clinically useful patient-reported outcome measures in software-assisted medication reviews.’ Contributed to the Jahrestagung der deutschen Gesellschaft für klinische Pharmazie, Heidelberg.

  • Opitz, Patrick; Stern, Mike; Hempel, Georg. „Entwicklung und Validierung einer quantitativen Methode zur Bestimmung von direkten oralen Antikoagulantien aus Kapillarblut unter Verwendung von VAMSTM und online SPE-LC-MS.“ contributed to the Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), digital, .
  • Spiegler V, Greiffer L, Jacobtorweihen J, Asase A, Lanvers-Kaminsky C, Hempel G, Agyare C, Hensel A. . ‘In vitro screening of plant extracts traditionally used as cancer remedies in Ghana - 15-Hydroxyangustilobine A as the active principle in Alstonia boonei leaves.’ Journal of Ethnopharmacology 2021. doi: 10.1016/j.jep.2020.113359.
  • Rimmler Ch, Lanckohr Ch, Mittrup M, Welp H, Würthwein G, Horn D, Fobker M, Ellger B, Hempel G. . ‘Population pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis during and after cardiopulmonary bypass.’ British Journal of Clinical Pharmacology 87, Nr. 3: 1486–1498.
  • Mc Laughlin AM, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland SL, Huitema ADR, Steeghs N, Müller L, Fuxius S, Illerhaus G, Joerger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C. . ‘Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. For The On-Target Study Consortium.’ Cancers 13, Nr. 24. doi: 10.3390/cancers1324628.
  • Blume H , Mehta M, Beuerle G, Dorantes A, Hempel G, Jiang W, Kovar A, Lee J , Potthast H, Schug B, Seidlitz A, Tampal N, Tsang Y, Walstab J, Welink J. . ‘The Global Bioequivalence Harmonisation Initiative (GBHI): Report of EUFEPS/AAPS fourth conference.’ European Journal of Pharmaceutical Sciences 2021. doi: 10.1016/j.ejps.2021.105987.
  • Barnett S, Hellmann F, Parke E, Makin G, Tweddle DA, Osborne C, Hempel G, Veal GJ. . ‘Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients.’ European Journal of Cancer (1965) 2021. doi: 10.1016/j.ejca.2021.09.014.
  • Jalusic KO, Hempel G, Arnemann PH, Spiekermann C, Kampmeier TG, Ertmer C, Gastine S, Hessler M. . ‘Population pharmacokinetics of vancomycin in patients with external ventricular drain-associated ventriculitis.’ British Journal of Clinical Pharmacology 87, Nr. 6.
  • Zubiaur P, Kneller LA, Ochoa D, Mejía G, Saiz-Rodríguez M, Borobia AM, Koller D, García IG, Navares-Gómez M, Hempel G, Abad-Santos F. . ‘Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.’ Clinical Pharmacokinetics 60, Nr. 2.
  • Gastine S, Hope W, Hempel G, Petraitiene R, Petraitis V, Mickiene D, Bacher J, Walsh TJ, Groll AH. . ‘Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.’ Antimicrobial Agents and Chemotherapy 65, Nr. 2. doi: 10.1128/AAC.01574-20.
  • Kneller LA, Zubiaur P, Koller D, Abad-Santos F, Hempel G. . ‘Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.’ Clinical Pharmacokinetics 2021, Nr. Jun 14. doi: 10.1007/s40262-021-01041-x.
  • Waltering Isabell, Schwalbe Olaf, Hempel Georg. . ‘Identification of factors for a successful implementation of medication reviews in community pharmacies: Using Positive Deviance in pharmaceutical care.’ International Journal of Clinical Pharmacy 44, Nr. 1. doi: 10.1007/s11096-021-01315-1.
  • Würthwein G, Lanvers-Kaminsky C, Siebel C, Gerß J, Möricke A, Zimmermann M, Stary J, Smisek P, Schrappe M, Rizzari C, Zucchetti M, Hempel G, Wicha SG, Boos J. . ‘Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data.’ European Journal of Drug Metabolism and Pharmacokinetics 46, Nr. 2: 289–300. doi: 10.1007/s13318-021-00670-8.
  • Shahhossini, Morwarid; Hessler, Michael; Hempel, Georg. „Untersuchung der Adsorption von Ciprofloxacin in vivo nach Hämoadsorption mit CytoSorb®.“ präsentiert auf der Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), digital, .
  • Schatz, L.M.; Ramadan, O.; Groll, A.; Masjosthusmann, K.; van den Heuvel, A.; Hempel, G. „Therapeutisches Drug Monitoring und Dosisoptimierung von Meropenem, basierend auf kleinen Probenvolumina bei kritisch kranken Kindern.“ präsentiert auf der Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), online, .
  • Maierhöfer, S; Waltering, I; Gillessen, A;Würthwein, G; Hempel, G. „Effekte Software-gestützter Medikationsanalysen auf die Angemessenheit der Medikation und auf patientenberichtete Endpunkte bei geriatrischen Patienten mit Polypharmazie: eine prospektive Analyse von Routinedaten aus öffentlichen Apotheken (OptiMed- Studienprotokoll).“ präsentiert auf der Annual Meeting of the German Society of Clinical Pharmacy - DGKPha, München, .
  • Maierhöfer S, Waltering I, Riebel S, Hempel G. „Effectiveness of clinical decision support systems for managing drug therapy: a systematic review within the scope of a clinical evaluation of a medical device.“ contributed to the 12th PCNE working conference, Basel, . doi: 10.1007/s11096-21-01269-4.
  • McLaughlin1, A.M.; Schmulenson2, E; Teplytska2, O; Zimmermann3, S; Opitz, P; Groenland4, S. L.; Huitema45, A. D.R.; Steeghs4; N.; Müller6, L.; Fuxius7, S.; Illerhaus8, G.; Joerger9, M.; Mayer10, F.; Fuhr11, U.; Holdenrieder12, S.; Hempel, G.; Scherf-Clavel3, O.; Jaehde2, U.; Kloft1, C. . ‘Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.’ Cancers 13, Nr. 24: 1–15. doi: 10.3390/cancers13246281.

  • Stern M, Giebels M, Fey T, Lübking M, Alferink J, Hempel G. . ‘Validation and clinical application of a volumetric absorptive microsampling method for 14 psychiatric drugs.’ Bioanalysis 2020 Aug;12(16). doi: 10.4155/bio-2020-0136.
  • Hempel G. . ‘Methods of Therapeutic Drug Monitoring including Pharmacogenetics 2nd Edition.’ In Handbook of Analytical Separations Series Volume 7:, edited by Elsevier B.V. Amsterdam, 1–355.
  • Hensel A, Bauer R, Heinrich M, Spiegler V, Kayser O, Hempel G, Kraft K. . ‘Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.’ Planta Medica 2020.
  • Hempel G. . ‘How physiologically-based pharmacokinetic models should be improved for drug development.’ Future Medicinal Chemistry 12, Nr. 12. doi: 10.4155/fmc-2020-0074.
  • Siebel C, Würthwein G, Lanvers-Kaminsky C, André N, Berthold F, Castelli I, Chastagner P, Doz F, English M, Escherich G, Frühwald MC, Graf N, Groll AH, Ruggiero A, Hempel G, Boos J. . ‘Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure.’ BMC pharmacology & toxicology 21, Nr. 1. doi: 10.1186/s40360-020-00417-2.
  • Dallmann A, Himstedt A, Solodenko J, Ince I, Hempel G, Eissing.T. . ‘Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery.’ Journal of Pharmacokinetics and Pharmacodynamics 47, Nr. 4.
  • Hellmann F, Völler S, Krischke M, Jamieson D, André N, Bisogno G, Boddy A, Hempel G. . ‘Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.’ European Journal of Drug Metabolism and Pharmacokinetics 45, Nr. 3.
  • Berning P, Hennemann C, Tulotta C, Schaefer C, Lechtape B, Hotfilder M, El Gourari Y, Jürgens H, Snaar-Jagalska E, Hempel G, Dirksen U, Potratz J. . ‘The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma.’ Cancers 12, Nr. 4.
  • Kneller, LA, Hempel, G. „Physiologically based pharmacokinetic modelling of risperidone and 9-hydroxyrisperidone to determine cytochrome P450 2D6 phenotypes in schizophrenia patients.“ contributed to the XIV th Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP, Mannheim, . doi: 10.1055/s-0040-1710122.
  • Kneller LA, Abad-Santos F, Hempel G. . ‘Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.’ Clinical Pharmacokinetics 59, Nr. 1. doi: 10.1007/s40262-019-00793-x.
  • Kneller LA, Hempel G. . ‘Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.’ Pharmaceutical Research 37, Nr. 6. doi: 10.1007/s11095-020-02843-7.
  • Zubiaur P, Kneller LA, Ochoa D, Mejía G, Saiz-Rodríguez M, Borobia AM, Koller D, García IG, Navares-Gómez M, Hempel G, Abad-Santos F. . ‘Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.’ Clinical Pharmacokinetics 60, Nr. 2. doi: 10.1007/s40262-020-00941-8.
  • Waltering I, Scheppe S, Kurth V, Hempel G, Jaehde U. . „Qualitätsindikatoren zur Bewertung von Medikationsanalysen in öffentlichen Apotheken. (Quality indicators for medication reviews in community pharmacies).“ Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 153-154. doi: 10.1016/j.zefq.2020.03.007.
  • Stern M, Giebels M, Fey T, Lübking M, Alferink J, Hempel G. . ‘Validation and clinical application of a volumetric absorptive microsampling method for 14 psychiatric drugs.’ Bioanalysis 12, Nr. 16. doi: 10.4155/bio-2020-0136.
  • Stern M, Hempel G. „Clinical validation study to derive conversion factors from capillary blood to plasma concentration for mirtazapine, quetiapine and norquetiapine.“ contributed to the IATDMCT 2020, Canada, .
  • Lücht UR, Geiben AK, Brune S, Scholz WU, Hempel G. „Using physiologically based pharmacokinetic (PBPK) modelling and SCHOLZ databank’s MDDI calculator (SDB-MDDI) to predict potential drug-drug interactions (DDI) of psychopharmaceuticals. .“ contributed to the XIVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP, Mannheim, . doi: 10.1055/s-0040-1710124.
  • Siebel Ch, Lanvers-Kaminsky C, Würthwein G, Hempel G, Boos J. . ‘Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring.’ Scientific Reports 1 Vol, Nr. 10: 18562. doi: 10.1038/s41598-020-75662.
  • Dellinger JK, Pitzer S, Schaffler-Schaden D, Schreier MM, Fährmann LS, Hempel G, Likar R, Osterbrink J, Flamm M. . ‘Improving medication appropriateness in nursing homes via structured interprofessional medication-review supported by health information technology: a non-randomized controlled study.’ BMC Geriatrics 20, Nr. 1: 506. doi: 10.1186/s12877-020-01895-z.
  • Siebel C, Lanvers-Kaminsky C, Würthwein G, Hempel G, Boos J. . ‘Bioanalysis of doxorubicin aglycone metabolites in human plasma samples-implications for doxorubicin drug monitoring.’ Scientific Reports 10, Nr. 1: 18562. doi: 10.1038/s41598-020-75662-w.
  • Khalil A, Würthwein G, Golitsch J, Hempel G, Fobker M, Gerss J, Möricke A, Zimmermann M, Smisek P, Zucchetti M, Nath C, Attarbaschi A, Stackelberg A, Gökbuget N, Rizzari C, Conter V, Schrappe M, Boos J, Lanvers-Kaminsky C. . ‘Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.’ Haematologica Online ahead of print. doi: 10.3324/haematol.2020.258525.

  • Lücht UR, Weber J, Scholz WU, Brune S, Hempel G. „Physiologically based pharmacokinetic modelling approach to assess drug-drug interactions (DDi) between psychopharmaceuticals - focus on mirtazapine and venlafaxine.“ contributed to the XXVIIIth Meeting of the Population Approach Group Europe - PAGE, Stockholm, Sweden, .
  • Hempel G. . ‘Pharmacotherapy in Children and Adolescents: Oncology.’ In Handb Exp Pharmacol, edited by Springer, 164–306. doi: 10.1007/164_2019_306.
  • Lehrnbecher T, Bochennek K, Klingebiel T, Gastine S, Hempel G, Groll AH. . ‘Extended Dosing Regimens for Fungal Prophylaxis.’ Clinical Microbiology Reviews 2019, Nr. 32(3).
  • Gastine S, Lanckohr C, Blessou M, Horn D, Fobker M, Bause D, Hempel G, Ellger B. . ‘Pharmacokinetics of Micafungin in Critically Ill Patients.’ Scientific Reports 9(1). doi: 10.1038/s41598-019-53093-6.
  • Jackson RK, Liebich M, Berry P, Errington J, Liu J, Parker C, Moppett J, Samarasinghe S, Hough R, Rowntree C, Goulden NJ, Vora A, Kearns PR, Saha V, Hempel G, Irving JAE, Veal GJ. . ‘Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia-a report from the UKALL 2011 trial.’ European Journal of Cancer 120. doi: 10.1016/j.ejca.2019.07.026.
  • Freundt JK, Frommeyer G, Spieker T, Wötzel F, Grotthoff JS, Stypmann J, Hempel G, Schäfers M, Jacobs AH, Eckardt L, Lange PS. . ‘Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure.’ BMC pharmacology & toxicology 2019, Nr. 20(1). doi: 10.1186/s40360-019-0294-x.
  • Pinder N, Zimmermann JB, Gastine S, Würthwein G, Hempel G, Bruckner T, Hoppe-Tichy T, Weigand MA, Swoboda S. . ‘Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling.’ Biomedicine & Pharmacotherapy 118: 109318. doi: 10.1016/j.biopha.2019.109318.
  • Kneller LA, Abad-Santos F, Hempel G. „Dose adjustment of risperidone in Cytochrome P450 2D6 intermediate- and poor metabolizer based on physiologically-based pharmacokinetic model.“ contributed to the Annual Meeting of the German Pharmaceutical Society – DPhG, Heidelberg, Germany, .
  • Kneller LA, Abad-Santos F, Hempel G. „Impact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach.“ contributed to the Annual Meeting of the population approach group in Europe [PAGE], Stockholm, Sweden, .

  • Ellermann I, Bueckmann A, Eveslage M, Buddendick H, Latal T, Niehoff D, Geissler RG, Hempel G, Kerkhoff A, Berdel WE, Roeder N, Van Aken HK, Zarbock A, Steinbicker AU. . ‘Treating Anemia in the Preanaesthesia Assessment Clinic: Results of a Retrospective Evaluation.’ Anesthesia and Analgesia 1. doi: 10.1213/ANE.0000000000003583.
  • Völler S, Pichlmeier U, Zens A, Hempel G. . ‘Pharmacokinetics of recombinant asparaginase in children with achute lymphoblastic leukemia.’ Cancer Chemotherapy and Pharmacology 81, Nr. 2: 305–314. doi: 10.1007/s00280-017-3492-5.
  • Agyare C, Spiegler V, Asase A, Scholz M, Hempel G, Hensel A. . ‘An ethnopharmacological survey of medicinal plants traditionally used for cancer treatment in the Ashanti region, Ghana.’ Journal of Ethnopharmacology 212: 137–152. doi: 10.1016/j.jep.2017.10.019.
  • Perego P, Hempel G, Linder S, Bradshaw TD, Larsen AK, Petres GJ, Philipps RM. . ‘Cellular pharmacology studies of anticancer agents:recommendations from the EORTIC-PAMM group.’ Cancer Chemotherapy and Pharmacology 81, Nr. 3: 427–441. doi: 10.1007/s00280-017-3502-7.
  • Völler S, Pichlmeier U, Zens A, Hempel G. . ‘Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.’ Cancer Chemotherapy and Pharmacology 81, Nr. 2: 305–314. doi: 10.1007/s00280-17-3492-5.
  • Dallmann A, Ince I, Coboeken K, Eissing T, Hempel G. . ‘A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.’ Clinical Pharmacokinetics 57, Nr. 6: 749–768. doi: 10.1007/s40262-017-0594-5.
  • Gastine S, Lehrnbecher T, Müller C, Farowski F, Bader P, Ullmann-Moskovits J, Cornely OA, Groll AH, Hempel G. . ‘Pharmacokinetic modeling of variconazole to develop an alternative dosing regimen in children.’ Antimicrobial Agents and Chemotherapy 62.
  • Agyare C, Spiegler V, Asase A, Scholz M, Hempel G, Hensel A. . ‘An ethnopharmacological survey of medicinal plants traditionally used for cancer treatment in the Ashanti region, Ghana.’ Journal of Ethnopharmacology 212: 137–152. doi: 10.1016/j.jep.2017.10.019.
  • Lücht UR, Weber J, Rimmler C, Scholz WU, Brune S, Hempel G. „Quantification of Pharmacokinetic Interactions: SCHOLZ Datenbank's MDDI-Calculator vs. Physiologically-Based Pharmacokinetic Modeling.“ contributed to the Annual Meeting of the German Pharmaceutical Society - DPhG, Hamburg, Germany, .
  • Kneller LA, Abad-Santos F, Hempel G. „Physiologically-based Pharmacokinetic Modelling of Risperidone and its Active Metabolite 9-Hydroxyrisperidone in Subjects Genotypes for Cytochrome P450 2D6.“ contributed to the Annual Meeting of the German Pharmaceutical Society – DPhG, Hamburg, Germany, .

  • Wähnert, Dirk; Roos, A, Glasbrenner J., Ilting-Reuke K., Ohrmann P., Hempel G., Duning T., Roeder N., Raschke M. . „Alterstraumatologie: Multimodale Delirprävention und Verwendung von Augmentationstechniken.“ Der Chirurg 88, Nr. 2: 95–104. doi: 10.1007/s00104-016-0339-2.
  • Dallmann A, Ince I, Solodenko, Meyer M, Willmann S, Eissing T, Hempel G. . ‘Physiological based pharmacokinetic modeling of renally cleared drugs in pregnant women.’ Clinical Pharmacokinetics 2017. doi: 10.1007/s40262-017-0538-0.
  • Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. . ‘Gestation-specific changes in the anatomy and physiology of healthy pregnant women:an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy.’ Clinical Pharmacokinetics 2017. doi: 10.1007/s40262-017-0539-z.
  • Radke C, Horn D, Lanckohr C, Ellger B, Meyer M, Eissing T, Hempel G. . ‘Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.’ Clinical Pharmacokinetics 56. doi: 10.1007/s40262-016-0475-3.
  • Würthwein G, Lanvers-Kaminsky C, Hempel G, Gastine S, Möricke A, Schrappe M, Karlsson M, Boos J. . ‘Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia.’ European Journal of Drug Metabolism and Pharmacokinetics 42, Nr. 6: 955–963. doi: 10.1007/s13318-017-0410-5.
  • Gastine S, Lehrnbecher T, Müller C, Farowski F, Bader P, Ullmann-Moskovits J, Cornely OA, Groll AH, Hempel G. . ‘Pharmakokinetic Modeling of Voriconazole to Develop an Alternative Dosing Regimen in Children.’ Antimicrobial Agents and Chemotherapy 62, Nr. 1. doi: 10.1128/AAC.01194-17.
  • Dickschen KJ, Willmann S, Hempel G, Block M. . ‘Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels.’ Frontiers in Pharmacology 8. doi: 10.33380/fphar.2017.00067.
  • Weber J, Oberfeld S, Bonse A, Telger K, Lingg R, Hempel G. . ‘Validation of a dried blood spot method for therapeutic drug monitoring of citalopram, mirtazapine and risperidone and its active metabolite 9-hydroxyrisperidone using HPLC–MS.’ Journal of Pharmaceutical and Biomedical Analysis 2017, Nr. 140.
  • Würthwein G, Lanvers-Kaminsky C, Hempel G, Gastine S, Möricke A, Schrappe M, Karlsson MO, Boos J. „Population Pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar® in children with ALL.“ contributed to the PAGE 26, Budapest, Ungarn, .
  • Wähnert D, Roos A, Glasbrenner J, Ilting-Reuke K, Ohrmann P, Hempel G, Duning T, Roeder N, Raschke MJ. . ‘Alterstraumatologie Multimodale Delirprävention und Verwendung von Augmentationstechniken.’ Der Chirurg 88.
  • Mahlknecht A, Nestler N, Bauer U, Schüßler N, Schuler J, Scharer S, Becker R, Waltering I, Hempel G, Schwalbe O, Flamm M, Osterbrink J. . ‘Effect of training and structured medication review on medication appropriateness in nursing home residents and on cooperation between health care professionals: the InTherAKT study protocol.’ BMC Geriatrics 17 (1).
  • Wähnert D, Roos A, Glasbrenner J, Ilting-Reuke K, Ohrmann P, Hempel G, Duning T, Roeder N, Raschke MJ. . „Alterstraumatologie Multimodale Delirprävention und Verwendung von Augmentationstechniken.“ Der Chirurg 88, Nr. 2: 95–104.
  • Völler S, Hempel G, Würthwein G, Boddy AV, Krischke M, André N, D'Incalci M, Bisogno G, Boos J. . ‘Towards a Model-Based Dose Recommendation for Doxorubicin in Children.’ Clinical Pharmacokinetics 56, Nr. 3: 215–223. doi: 10.1007/s40262-016-0451-y.

  • Liebich M, Hempel G. „Glucose as a cryoprotectant to stabilize liposomal daunorubicin (DaunoXome®) in frozen plasma for pharmacokinetic investigations.“ contributed to the EORTC-PAMM Winter, Antwerpen, Begium, .
  • Radke C, Horn D, Lanckohr C, Ellger B, Meyer M, Eissing T, Hempel G. „Development of a PBPK approach to predict the pharmacokinetics in patients with sepsis.“ contributed to the PAGE, Lissabon,Portugal, .
  • Waltering I, Schwalbe O, Hempel G. . ‘Information content of medication schedules prior to the implementation of the federal standard medication plan.’ Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 115-1.
  • Krischke M, Hempel G, Völler S, Andrè N, D'Incalci M, Bisogno G, Köpcke W, Borowski M, Herold R, Boddy AV, Boos J. . ‘Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" Trial.’ Cancer Chemotherapy and Pharmacology 21.
  • Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Thèoret Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ. . ‘Association of busulfan eyposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.’ The Lancet Haematology 13.
  • Usman M, Hempel G. . ‘Development and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA).’ SpringerPlus 5. doi: 10.1186/s40064-016-1778-4.
  • John C, Herz T, Boos J, Langer K, HempelG. . ‘Asymmetrial flow field-flow fractionation for the analysis of PEG-asparaginase.’ Talanta 146: 335–339.
  • Lanckohr C, Horn D, Voeller S, Hempel G, Fobker M, Welp H, Koeck R, Ellger B. . ‘Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery.’ Journal of Thoracic and Cardiovascular Surgery 152, Nr. 2: 603–610. doi: 10.1016/j.jtcvs.2016.04.024.
  • Krischke M, Hempel G, Völler S, André N, D’Incalci M, Bisogno G, Köpcke W, Borowski M, Herold R, Boddy AV, Boos J. . ‘Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial.’ Cancer Chemotherapy and Pharmacology 78, Nr. 6: 1175–1184. doi: 10.1007/s00280-016-3174-8.
  • John C, Herz T, Boos J, Langer K, Hempel G. . ‘Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase.’ Talanta 146: 335–339. doi: 10.1016/j.talanta.2015.08.028.

  • Henrichsmann M, Hempel G. . ‘Impact of medication therapy management in patients with Parkinson's disease.’ International Journal of Clinical Pharmacy 38, Nr. 1: 54–60. doi: 10.1007/s11096-015-0206-0.
  • Goedecke S, Mühlisch J, Hempel G, Frühwald MC, Wünsch B. . ‘Quantitative analysis of DNA methylation in the promoter region of the methylguanine-O6-DNA-methyltransferase gene by COBRA and subsequent native capillary gel electrophoresis.’ Electrophoresis 2015. doi: 10.1002/elps.201500242.
  • John C., Herz T., Boos J., Langer K., Hempel G. . ‘A novel asymmetrical flow field-flow fractionation for the analysis of PEG asparaginase.’ Talanta 146: 335–339.
  • Horn D, Hempel G. . „Spesis.“ In Angewandte Pharmakotherapie, herausgegeben von Rose O, Friedland K, 575–584. 1. Aufl. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
  • Hempel G, Ritter J. . „Leukämie.“ In Angewandte Pharmakotherapie, herausgegeben von Rose O, Friedland K, 442–462. 1. Aufl. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
  • Waltering I, Schwalbe O, Hempel G. . ‘Discrepancies on Medication Plans detected in German Community Pharmacies.’ Journal of Evaluation in Clinical Practice 21, Nr. 21(5): 886–892.
  • Völler S, Boos J. Krischke M, Würthwein G, Kontny NE, Boddy AV, Hempel G. . ‘Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.’ Clinical Pharmacokinetics 54: 1139–1149. doi: 10.1007/s40262-015-0272-4.
  • Stader F, Wuerthwein G, Groll AH, Vehreschild JJ, Cornely OA, Hempel G. . ‘Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.’ Pharmaceutical Research 32: 2029–2037.
  • Drogouti E., Pana Z., Tragiannidis A., Hempel G., Groll A. . ‘Clinical pharmacology of itraconazole in children and adolescents.’ Current Fungal Infection Reports 9, Nr. 2: 65–73. doi: 10.1007/s12281-015-0218-1.

  • Bernemann C, Hülswig C, Ruckert C, Schäfer S, Blümel L, Hempel G, Götte M, Greve B, Barth PJ, Kiesel L, Liedtke C. . ‘Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.’ Molecular Cancer 2014, Nr. 13: 174. doi: 10.1186/1476-4598-13-174.
  • Hempel G. . ‘Physiology-Based Pharmacokinetic Modeling - Promise for Paediatric Drug Development?’ Current Fungal Infection Reports 8: 67–71.
  • Geier AS, Wellmann I, Wellmann J, Kajüter H, Heidinger O, Hempel G, Hense HW. . ‘Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus.’ Diabetes Research and Clinical Practice 106: 73–80.
  • Diestelhorst C, Boos J, McCune JS, Russell J, Kangarloo SB, Hempel G. . ‘Predictive Performance of a Physilogocally Based Pharmacokinetic Model of Busulfan in Children.’ Pediatric Hematology-Oncology 2014, Nr. 31(8): 731–742. doi: 10.3109/08880018.2014.927945.
  • Dickschen K, Eissing T, Mürdter T, Schwab M, Willmann S, Hempel G. . ‘Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.’ SpringerPlus 5, Nr. 3: 285.
  • Borghorst S, Hempel G, Poppenborg S, Franke D, König T, Baumgart J. . ‘Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli L-asparaginase preparation (MC0609) in Beagle dog.’ Cancer Chemotherapy and Pharmacology 74: 367–378.
  • Diestelhorst C, Boos J, McCune JS, Hempel G. . ‘Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM model to optimize dosing.’ European Journal of Clinical Pharmacology 70, Nr. 7: 839–847. doi: 10.1007/s00228-014-1692-z.
  • Kerl K, Diestelhorst C, Bartelink I, Boelens J, Trame MN, Boos J, Hempel G. . ‘Evaluation of effects of busulfan and DMA on SOS in pedriatic stem cell recipients.’ Pediatric Blood and Cancer 61: 306–311. doi: 10.1002/pbc.24827.
  • Kerl K, Diestelhorst C, Bartelink I, Boelens J, Trame MN, Boos J, Hempel G. . ‘Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients.’ Pediatric blood & cancer 61, Nr. 2: 306–311. doi: 10.1002/pbc.24827.

  • Würthwein G, Cornely OA, Trame M, Vehreschild JJ, Vehreschild MJ, Farowski F, Müller C, Boos J, Hempel G, Hallek M, Groll AH. . ‘Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.’ Antimicrobial Agents and Chemotherapy 57, Nr. 4: 1664–1671.
  • Trame MN, Bartelink IH, Boos J, Boelens JJ, Hempel G. . ‘Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.’ Cancer Chemotherapy and Pharmacology 72, Nr. 5: 1149–1155. doi: 10.1007/s00280-013-2284-9.
  • Diestelhorst C, Boos J, McCune JS, Russell J, Kangarloo SB, Hempel G. . ‘Physiologically based pharmacokinetic modelling of Busulfan: A new approach to describe and predict the pharmacokinetics in adults.’ Cancer Chemotherapy and Pharmacology 72, Nr. 5: 991–1000. doi: 10.1007/s00280-013-2275-x.
  • Geier A.S., Wellmann J., Wellmann I., Kajuter H., Heidinger O., Hempel G., Hense H.W. . ‘Cancer detection rates following enrolment in a disease management programme for type 2 diabetes.’ Diabetologia 56, Nr. 9: 1944–1948. doi: 10.1007/s00125-013-2947-4.
  • Kontny NE, Würthwein G, Boos J, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G. . ‘Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.’ Cancer Chemotherapy and Pharmacology 71, Nr. 3: 749–763. doi: 10.1007/s00280-013-2069-1.
  • Henschel AD, Rothenberger LG, Schrey D, Gerß J, Hempel G, Boos J. . ‘Risk and benefit from clinical trials in minors: Making the case for transparent and consistent publications.’ Open Journal of Pediatrics 03, Nr. 02: 151–164. doi: 10.4236/ojped.2013.32027.

  • Storzinger D., Borghorst S., Hofer S., Busch C.J., Lichtenstern C., Hempel G., Weigand M.A., Hoppe-Tichy T. . ‘Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit.’ Antimicrobial Agents and Chemotherapy 56, Nr. 8: 4468–4470. doi: 10.1128/AAC.06167-11.
  • Dickschen K., Willmann S., Thelen K., Lippert J., Hempel G., Eissing T. . ‘Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance.’ Frontiers in Pharmacology null, Nr. null. doi: 10.3389/fphar.2012.00092.
  • Falck E., Groenhagen A., Muhlisch J., Hempel G., Wunsch B. . ‘Genome-wide DNA methylation level analysis by micellar electrokinetic chromatography and laser-induced fluorescence detection after treatment of cell lines with azacytidine and antifolates.’ Analytical Biochemistry 421, Nr. 2: 439–445. doi: 10.1016/j.ab.2011.09.027.
  • Fischer U., Schuler K., Siebert S., Smollich M., Elkeles B., Hempel G., Kruse J. . „Formulation - Quality in seven steps. Step 1: Comply with hygiene standards.“ Deutsche Apotheker-Zeitung 152, Nr. 37: 62–73.
  • Bartelink I.H., Boelens J.J., Bredius R.G.M., Egberts A.C.G., Wang C., Bierings M.B., Shaw P.J., Nath C.E., Hempel G., Zwaveling J., Danhof M., Knibbe C.A.J. . ‘Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: Towards individualized dosing.’ Clinical Pharmacokinetics 51, Nr. 5: 331–345. doi: 10.2165/11598180-000000000-00000.
  • Trame MN, Bergstrand M, Karlsson MO, Hempel G. . ‘Population Pharmacokinetics of Busulfan in Children-Response.’ Clinical Cancer Research 18, Nr. 9: 2717–2718. doi: 10.1158/1078-0432.CCR-12-0425.
  • Kontny NE, Boos J, Würthwein G, Hempel G, Boddy AV, Groll AH, Krischke M. . ‘Minization of the preanalytical error in pharmacokinetic analyses and therapeutic drug monitoring: focus on IV drug administration.’ Therapeutic Drug Monitoring 34, Nr. 4: 460–466. doi: 10.1097/FTD.0b013e31825a4d9c.
  • Borghorst S, Pieters R, Kuehnel HJ, Boos J, Hempel G. . ‘Population pharmacokinetics of native Escheria coli asparaginase.’ Clinical Trials 29, Nr. 2: 154–165. doi: 10.3109/08880018.2011.627978.
  • Siebert S, Elkeles B, Hempel G, Kruse J, Smollich M. . „Die PRISCUS-Liste im klinischen Test; Praktikabilität und Vergleich mit internationalen PIM-Listen.“ Zeitschrift für Gerontologie und Geriatrie 46: 35–47.
  • Reimer J, Bien S, Ameling S, Hammer E, Völker U, Hempel G, Boss J, Kroemer HK, Ritter CA. . ‘Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.’ European Journal of Clinical Pharmacology 68, Nr. 6: 923–935. doi: 10.1007/s00228-011-1209-y.
  • Kersting G, Willmann S, Würthwein G, Lippert J, Boos J, Hempel G. . ‘Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.’ Cancer Chemotherapy and Pharmacology 69, Nr. 2: 397–405. doi: 10.1007/s00280-011-1706-9.
  • Würthwein G, Young C, Lanvers-Kaminsky C, Hempel G, Trame M, Schwerdtfeger R, Ostermann H, Heinz W, Cornely O, Kolve H, Boos J, Silling G, Groll A. . ‘Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.’ Antimicrobial Agents and Chemotherapy 56, Nr. 1: 536–543. doi: 10.1128/AAC.00265-11.

  • Kontny NE, Hempel G, Boos J, Boddy AV, Krischke M. . ‘Minimization of the preanalytical error in plasma samples for pharmacokinetic analyses and therapeutic drug monitoring-using doxorubicin as an example.’ Therapeutic Drug Monitoring 33, Nr. 6: 766–771. doi: 10.1097/FTD.0b013e31823aa8ab.
  • Hempel G., Trame M.N. . ‘Therapeutic drug monitoring of busulfan.’ Clinical Chemistry 57, Nr. 4: 643–644. doi: 10.1373/clinchem.2010.155374.
  • Trame MN, Bergstrand M, Karlsson MO, Boos J, Hempel G. . ‘Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.’ Clinical Cancer Research 17, Nr. 21: 6867–6877. doi: 10.1158/1078-0432.CCR-11-0074.
  • Hempel G, Baum S (Hrsg.): . Geriatrische Pharmazie. 1. Aufl. Govi-Verlag: Govi.
  • Horn DG, Trame MN, Hempel G. . ‘The management of hypertensive emergencies in children after stem cell transplantation.’ International Journal of Clinical Pharmacy 33: 165–176.

  • Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag H-G, Haefeli WE, Hempel G, Hoppe-Tichy T, Weigand MA. . ‘Pharmacokinetics of linezolid in septic patients with and without extended dialysis.’ European Journal of Clinical Pharmacology 66, Nr. 3: 291–298. doi: 10.1007/s00228-009-0766-9.
  • Trame MN, Mitchell L, Krümpel A, Male C, Hempel G, Nowak-Göttl U. . ‘Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: A cohort study.’ Journal of Thrombosis and Haemostasis 8, Nr. 9: 1950–1958. doi: 10.1111/j.1538-7836.2010.03964.x.
  • Hempel G, Müller HJ, Lanvers-Kaminsky C, Würthwein G, Hoppe A, Boos J. . ‘A population pharmacokinetic model for pegylated-asparaginase in children.’ British Journal of Haematology 148, Nr. 1: 119–125. doi: 10.1111/j.1365-2141.2009.07923.x.
  • Hempel G, Relling MV, de Rossi G, Stary J, De Lorenzo P, Valsecchi MG, Barisone E, Boos J, Pieters R. . ‘Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.’ Pediatric Blood and Cancer 54, Nr. 3: 355–360. doi: 10.1002/pbc.22266.
  • Schrey D, Borghorst S, Lanvers-Kaminsky C, Hempel G, Gerss J, Möricke A, Schrappe M, Boos J. . ‘Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.’ Pediatric Blood and Cancer 54, Nr. 7: 952–958. doi: 10.1002/pbc.22417.
  • Niemann A, Mühlisch J, Frühwald MC, Gerss J, Hempel G, Boos J. . ‘Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?’ Therapeutic Drug Monitoring 32, Nr. 4: 467–475. doi: 10.1097/FTD.0b013e3181e5c6b3.

  • Goedecke S, Schlosser S, Muhlisch J, Hempel G, Fruhwald MC, Wünsch B. . ‘Determination of DNA methylation by COBRA: A comparative study of CGE with LIF detection and conventional gel electrophoresis.’ Electrophoresis 30, Nr. 17: 3063–3070. doi: 10.1002/elps.200900204.
  • Schrauder A, Saleh S, Sykora KW, Hoy H, Welte K, Boos J, Hempel G, Grigull L. . ‘Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough.’ Pediatric Transplantation 13, Nr. 4: 444–450. doi: 10.1111/j.1399-3046.2008.00968.x.
  • Goedecke S, Schlosser S, Mühlisch J, Hempel G, Frühwald MC, Wünsch B. . ‘Accurate quantification of DNA methylation of DRD4 applying capillary gel electrophoresis with LIF detection.’ Electrophoresis 30, Nr. 8: 1412–1417. doi: 10.1002/elps.200800567.
  • Groll AH, Young C, Lanvers-Kaminsky C, Silling G, Hempel G, Boos J, Wurthwein G. „Population pharmacokinetics of liposomal amphotericin B, caspofungin and the combination of both in allogeneic hematopoietic stem cell recipients.“ contributed to the 4th Trends in Medical Mycology, Athen, Deutschland, . doi: 10.1111/j.1439-0507.2009.01782.x.

  • Koling S, Hempel G. . „Arzneimitteltherapie im Kindesalter: Die sichere und effektive Dosis finden.“ Pz Prisma 15, Nr. 2: 68–78.
  • Groenhagen A, Kallinger B, Hempel G, Lanvers-Kaminsky C, Muhlisch J, Boos J, Jurgens H, Fruhwald MC. . ‘The impact of antifolate therapy on the genome and epigenome.’ Klinische Pädiatrie 220, Nr. 3: 201–201.
  • Niemann A, Boos J, Muhlisch J, Fruhwald MC, Hempel G. . ‘Determination of methotrexate and its main metabolite in cerebrospinal fluid after High-Dose Methotrexate by LC-MS.’ Klinische Pädiatrie 220, Nr. 3: 205–205.
  • Hempel G. . „Kommentar zur Monographie Paclitaxel des Europäischen Arzneibuchs.“ In Kommentar zum Ph. Eur. Ausgabe 5.8, herausgegeben von Scriba G. Stuttgart: Wissenschaftliche Verlagsgesellschaft. [online first]

  • Hempel G, Boos J. . ‘Comment on "Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation" by F.K. Glowka et al. [J. Chromatogr. B 850 (2007) 569-574].’ Journal of Chromatography B 853, Nr. 1-2: 369–370.
  • Hempel G, Oechtering D, Lanvers-Kaminsky C, Klingebiel T, Vormoor J, Gruhn B, Boos J. . ‘Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan.’ Journal of Clinical Oncology 25, Nr. 13: 1772–1778. doi: 10.1200/JCO.2006.08.8807.
  • Hempel G, Boos J. . ‘Flat-fixed dosing versus body surface area-based dosing of anticancer drugs: There is a difference.’ Oncologist 12, Nr. 8: 924–926. doi: 10.1634/theoncologist.12-8-924.
  • Koling S, Hempel G, Lanvers C, Boos J, Würthwein G. . ‘Monitoring paracetamol metabolism after single and repeated administration in pediatric patients with neoplastic diseases.’ International Journal of Clinical Pharmacology and Therapeutics 45, Nr. 9: 496–503. doi: 10.5414/cpp45496.
  • Hunz M, Jetter A, Warm M, Pantke E, Tuscher M, Hempel G, Jaehde U, Untch M, Kurbacher C, Fuhr U. . ‘Plasma and tissue pharmacokinetics of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.’ Clinical Pharmacology and Therapeutics 81, Nr. 5: 659–668. doi: 10.1038/sj.clpt.6100067.
  • Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, De Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AHGJ, Twelves C, Beijnen JH, Schellens JHM. . ‘Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG.’ Clinical Pharmacokinetics 46, Nr. 12: 1051–1068. doi: 10.2165/00003088-200746120-00005.
  • Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Schwab M, Diehl V, Fuhr U. . ‘Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.’ Clinical Pharmacokinetics 46, Nr. 4: 319–333. doi: 10.2165/00003088-200746040-00005.
  • Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G. . ‘Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.’ Cancer 110, Nr. 1: 103–111. doi: 10.1002/cncr.22739.
  • Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert AH, Boddy A, Hollema H, Fety R, Van der Vijgh WJF, Hempel G, Chatelut E, Karlsson M, Tranchand B, Schrijvers AHGJ, Beijnen JH, Schellens JHM. . ‘Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG.’ British Journal of Clinical Pharmacology 63, Nr. 4: 505. doi: 10.1111/j.1365-2125.2007.02886_4.x.
  • Hempel G. . „Populationspharmakokinetik.“ In Repetitorium Klinische Pharmazie, herausgegeben von Högger P, Strehl E, 38–46. Eschborn: Govi.
  • Hempel G. . „Pharmakogenetik.“ In Repetitorium Klinische Pharmazie, herausgegeben von Högger P, Strehl E, 43–46. Eschborn: Govi.
  • Hempel G, Boos J. . ‘Comment on "Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation" by F.K. Glowka et al. J. Chromatogr. B 850 (2007) 569-574.’ Journal of Chromatography B 853, Nr. 1-2: 369–370. doi: 10.1016/j.jchromb.2007.02.060.
  • Hempel G, Boos J. . ‘Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference.’ Oncologist 12, Nr. 8: 924–926. doi: 10.1634/theoncologist.12-8-924.

  • Ünsalan S, Hempel G, Fobker M, Würthwein G, Boos J. . ‘Monitoring of mycophenolic acid in the plasma of transplant patients by capillary electrophoresis.’ Chromatographia 64, Nr. 7-8: 419–421. doi: 10.1365/s10337-006-0046-0.
  • Oechtering D, Boos J, Hempel G. . ‘Monitoring of N,N-dimethylacetamide in children during i.v.-busulfan therapy by liquid chromatography-mass spectrometry.’ Journal of Chromatography B 838, Nr. 2: 129–134. doi: 10.1016/j.jchromb.2006.04.034.
  • Saleh S, Hempel G. . ‘Quantification of ganciclovir in human plasma using capillary electrophoresis.’ Electrophoresis 27, Nr. 12: 2439–2443. doi: 10.1002/elps.200500903.
  • Lanvers-Kaminsky C, Hempel G. . ‘Preclinical and Clinical Aspects of Asparaginase.’ European Journal of Hospital Pharmacy: Science and Practice 12, Nr. 5: 45–46.
  • Hempel G. . „Kommentar zur Monographie Buspironhydrochlorid des Europäischen Arzneibuchs.“ In Kommentar zum Ph. Eur. Ausgabe 5.4, herausgegeben von Scriba G. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
  • Hempel G. . „Kommentar zur Monographie Emedastindifumarat des Europäischen Arzneibuchs.“ In Kommentar zum Ph. Eur. Ausgabe 5.4, herausgegeben von Scriba G. Stuttgart: Wissenschaftliche Verlagsgesellschaft.

  • Lingg RM, Hempel G, Rots MG, Van Zantwijk CH, Boos J, Kaspers GJL. . ‘Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay.’ Cancer Chemotherapy and Pharmacology 56, Nr. 3: 322–327. doi: 10.1007/s00280-005-1032-1.
  • Hempel G, Lingg R, Boos J. . ‘Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: Implications for the application in case of methotrexate intoxications.’ Cancer Chemotherapy and Pharmacology 55, Nr. 4: 347–353. doi: 10.1007/s00280-004-0910-2.
  • Oechtering D, Schiltmeyer B, Hempel G, Schwab M, Würthwein G, Mürdter T, Klingebiel T, Vormoor J, Gruhn B, Fleischack G, Boos J. . ‘Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation.’ Anti-Cancer Drugs 16, Nr. 3: 337–344. doi: 10.1097/00001813-200503000-00014.
  • Würthwein G, Koling S, Reich A, Hempel G, Schulze-Westhoff P, Pinheiro PV, Boos J. . ‘Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery.’ European Journal of Clinical Pharmacology 60, Nr. 12: 883–888. doi: 10.1007/s00228-004-0873-6.
  • Würthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. . ‘Population pharmacokinetics of amphotericin B lipid complex in neonates.’ Antimicrobial Agents and Chemotherapy 49, Nr. 12: 5092–5098. doi: 10.1128/AAC.49.12.5092-5098.2005.
  • Würthwein G, Koling S, Reich A, Hempel G, Schulze-Westhoff P, Pinheiro PV, Boos J. . ‘Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery.’ European Journal of Clinical Pharmacology 60, Nr. 12: 883–888. doi: 10.1007/s00228-004-0873-6.

  • Hempel G. . ‘Dose and therapy individualisation in cancer chemotherapy.’ In Drug Monitoring and Clinical Chemistry, Handbook of Analytical Seperations Vol 5, edited by Hempel G, 169–194. Amsterdam: Elsevier. doi: 10.1016/S1567-7192(04)80008-1.

  • Flege S, Griese N, Hempel G. . „Drug Monitoring von Anthrazyklinen: Teil 1: Chemie, Wirkung, Nebenwirkung und Pharmakokinetik.“ Pz Prisma 10, Nr. 1: 29–36.
  • Flege S, Griese N, Hempel G. . „Drug Monitoring von Anthrazyklinen Teil 2: Monitoring bei Kindern, Reduktion der Kardiotoxizität, Fallbeispiele.“ Pz Prisma 10, Nr. 2: 105–117.
  • Hempel G, Reinhardt D, Creutzig U, Boos J. . ‘Population pharmacokinetics of liposomal daunorubicin in children.’ British Journal of Clinical Pharmacology 56, Nr. 4: 370–377. doi: 10.1046/j.1365-2125.2003.01886.x.
  • Hempel G, Rübe C, Mosler C, Wienstroer M, Wagner-Bohn A, Schuck A, Willich N, Boos J. . ‘Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors.’ Anti-Cancer Drugs 14, Nr. 6: 417–422. doi: 10.1097/00001813-200307000-00005.
  • Schiltmeyer B, Klingebiel T, Schwab M, Mürdter TE, Ritter CA, Jenke A, Ehninger G, Gruhn B, Würthwein G, Boos J, Hempel G. . ‘Population pharmacokinetics of oral busulfan in children.’ Cancer Chemotherapy and Pharmacology 52, Nr. 3: 209–216. doi: 10.1007/s00280-003-0631-y.
  • Hempel G. . ‘Biomedical applications of capillary electrophoresis.’ Clinical Chemistry and Laboratory Medicine 41, Nr. 6: 720–723. doi: 10.1515/CCLM.2003.111.

  • Griese N, Blaschke G, Boos J, Hempel G. . ‘Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis.’ Journal of Chromatography A 979, Nr. 1-2: 379–388. doi: 10.1016/S0021-9673(02)01440-1.
  • Lingg RM, Rots MG, Van Zantwijk CH, Hempel G, Kaspers GJL, Boos J. . ‘Effect and interaction of 7-hydroxy methotrexate and methotrexate in AML and ALL patients samples: Measured by the thymidylate synthase inhibition assay.’ International Journal of Clinical Pharmacology and Therapeutics 40, Nr. 8: 382–384.
  • Hempel G, Flege S, Würthwein G, Boos J. . ‘Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.’ Cancer Chemotherapy and Pharmacology 49, Nr. 2: 133–141. doi: 10.1007/s00280-001-0392-4.
  • Busse D, Würthwein G, Hinske C, Hempel G, Fromm MF, Eichelbaum M, Kroemer HK, Busch FW. . ‘Pharmacokinetics of intravenous etoposide in patients with breast cancer: Influence of dose escalation and cyclophosphamide and doxorubicin coadministration.’ Naunyn-Schmiedeberg's Archives of Pharmacology 366, Nr. 3: 218–225. doi: 10.1007/s00210-002-0594-2.
  • Schiltmeyer B, Hempel G, Schwab M, Ritter C, Klingebiel T, Boos J. . ‘Population pharmacokinetics of oral busulfan in children.’ International Journal of Clinical Pharmacology and Therapeutics 40, Nr. 8: 385–386.
  • Reinhardt D, Hempel G, Fleischhack G, Schulz A, Boos J, Creutzig U. . „Effektive Rezidivtherapie der akuten myeloischen Leukämie im Kindesalter mit liposomalem Daunorubicin und Cytarabin.“ Klinische Pädiatrie 214, Nr. 4: 188–194. doi: 10.1055/s-2002-33185.
  • Wilde S, Jetter A, Zaigier M, Rietbrock S, Menzel H, Sieber M, Tesch H, Hempel G, Busse D, Schwab M, Reif S, Jaehde U, Diehl V, Fuhr U. . ‘Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy.’ International Journal of Clinical Pharmacology and Therapeutics 40, Nr. 12: 586–588.
  • Lanvers C, Pinheiro JPV, Hempel G, Wuerthwein G, Boos J. . ‘Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum.’ Analytical Biochemistry 309, Nr. 1: 117–126. doi: 10.1016/S0003-2697(02)00232-4.

  • Ünsalan S, Hempel G, Boos J, Blaschke G. . ‘Determination of mycophenolic acid and its glucuronide conjugate in human plasma by capillary electrophoresis.’ Chromatographia 54, Nr. 9-10: 635–637. doi: 10.1007/BF02492191.
  • Laubrock N, Schulze-Westhoff P, Würthwein G, Flege S, Lanvers C, Hempel G. . „Drug-monitoring von Anthracyclinen - Untersuchungen zur Minimierung präanalytischer Fehler bei der Gewinnung von Plasmaproben.“ Krankenhauspharmazie KPH 22, Nr. 4: 166–169.
  • Wessel T, Breitkreutz J, Ahlke E, Hempel G, Boos J. . „Probleme bei der Dauertherapie mit Mercaptopurin-Tabletten.“ Krankenhauspharmazie KPH 22, Nr. 7: 325–329.
  • Hempel G, Schulze-Westhoff P, Flege S, Boos J. . ‘Quantification of daunorubicin and daunorubicinol in plasma by capillary electrophoresis.’ Journal of chromatography B: Biomedical sciences and applications 758, Nr. 2: 221–228. doi: 10.1016/S0378-4347(01)00185-2.
  • Soetebeer UB, Schierenberg M-O, Schulz H, Hempel G, Andresen P, Blaschke G. . ‘Simultaneous quantification of etoposide and etoposide phosphate in human plasma by capillary electrophoresis using laser-induced native fluorescence detection.’ Analytical Chemistry 73, Nr. 10: 2178–2182. doi: 10.1021/ac001467v.
  • Wessel Torsten, Breitkreutz Jörg, Ahlke Elvira, Hempel Georg, Boos Joachim. . „Probleme bei der Dauertherapie mit Mercaptopurin-Tabletten.“ Krankenhauspharmazie 22, Nr. 7: 325–329.
  • Flege S, Hempel G, Schulze-Westhoff P, Laubrock N, Boos J. . ‘Drug Monitoring of Doxorubicin in Children.’ In Acute Leukemias VIII, edited by Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, Creutzig U, 223–226. Berlin, Heidelberg: Springer VDI Verlag.
  • Wessel T, Hempel G, Boos J. . ‘Drug Monitoring during Maintenance Therapy in Children with ALL.’ In Acute Leukemias VIII, edited by Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, Creutzig U, 231–235. Berlin, Heidelberg: Springer VDI Verlag. doi: 10.1007/978-3-642-18156-6_40.

  • Wessel T, Lanvers C, Fruend S, Hempel G. . ‘Determination of purines including 2,8-dihydroxyadenine in urine using capillary electrophoresis.’ Journal of Chromatography A 894, Nr. 1-2: 157–164. doi: 10.1016/S0021-9673(00)00439-8.
  • Hempel G. . ‘Strategies to improve the sensitivity in capillary electrophoresis for the analysis of drugs in biological fluids.’ Electrophoresis 21, Nr. 4: 691–698. doi: 10.1002/(SICI)1522-2683(20000301)21:4691::AID-ELPS691>3.0.CO;2-U.
  • Laubrock N, Hempel G, Schulze-Westhoff P, Würthwein G, Flege S, Boos J. . ‘The stability of doxorubicin and idarubicin in plasma and whole blood.’ Chromatographia 52, Nr. 1-2: 9–13. doi: 10.1007/BF02490784.
  • Hempel G, Rube C, Mosler C, Lehmkuh D, Wienstroer M, Wagner A, Schuck A, Willich N, Boos J. . ‘Pharmacokinetics of low-dose paclitaxel in patients with brain tumors.’ International Journal of Clinical Pharmacology and Therapeutics 38, Nr. 3: 158–159.
  • Wilde S, Jetter A, Menzel H, Rietbrock S, Zaigler M, Sieber M, Tesch H, Hempel G, Reif S, Jaehde U, Merkel U, Johnson S, Diehl V, Fuhr U. . ‘Population pharmacokinetics of drugs in the BEACOPP chemotherapy regimen used in Hodgkin's disease.’ International Journal of Clinical Pharmacology and Therapeutics 38, Nr. 3: 147–149.
  • Laubrock N, Hempel G, Schulze-Westhoff P, Würthwein G, Flege S, Boos J. . ‘The stability of doxorubicin and ldarubicin in plasma and whole blood.’ Chromatographia 52, Nr. 1-2: 9–13. doi: 10.1007/BF02490784.

  • Olgemöller J, Hempel G, Boos J, Blaschke G. . ‘Determination of (E)-5-(2-bromovinyl)-2'-deoxyuridine in plasma and urine by capillary electrophoresis.’ Journal of chromatography B: Biomedical sciences and applications 726, Nr. 1-2: 261–268. doi: 10.1016/S0378-4347(98)00573-8.
  • May-Manke A, Kroemer H, Hempel G, Bohnenstengel F, Hohenlöchter B, Blaschke G, Boos J. . ‘Investigation of the major human hepatic cytochrome P450 involved in 4- hydroxylation and N-dechloroethylation of trofosfamide.’ Cancer Chemotherapy and Pharmacology 44, Nr. 4: 327–334. doi: 10.1007/s002800050985.
  • Pinheiro JPV, Ahlke E, Nowak-Göttl U, Hempel G, Müller HJ, Lümkemann K, Schrappe M, Rath B, Fleischhack G, Mann G, Boos J. . ‘Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols.’ British Journal of Haematology 104, Nr. 2: 313–320. doi: 10.1046/j.1365-2141.1999.01192.x.
  • Wagner A, Hempel G, Gumbinger HG, Jürgens H, Boos J. . ‘Pharmacokinetics of anticancer drugs in vitro.’ Advances in Experimental Medicine and Biology 457: 397–407. doi: 10.1007/978-1-4615-4811-9_42.
  • May-Manke A, Kroemer H, Hempel G, Bohnenstengel F, Hohenlöchter B, Blaschke G, Boos J. . ‘Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide.’ Cancer Chemotherapy and Pharmacology 44, Nr. 4: 327–334. doi: 10.1007/s002800050985.
  • Olgemöller J, Hempel G, Boos J, Blaschke G. . ‘Determination of (E)-5-(2-bromovinyl)-2′-deoxyuridine in plasma and urine by capillary electrophoresis.’ Journal of Chromatography - Biomedical Applications 726, Nr. 1-2: 261–268. doi: 10.1016/s0378-4347(98)00573-8.

  • Sczesny F, Hempel G, Boos J, Blaschke G. . ‘Capillary electrophoretic drug monitoring of methotrexate and leucovorin and their metabolites.’ Journal of Chromatography B: Biomedical applications 718, Nr. 1: 177–185. doi: 10.1016/S0378-4347(98)00367-3.
  • Lanvers C, Hempel G, Blaschke G, Boos J. . ‘Chemically induced isomerization and differential uptake modulate retinoic acid disposition in HL-60 cells.’ FASEB journal : official publication of the Federation of American Societies for Experimental Biology 12, Nr. 15: 1627–1633. doi: 10.1096/fasebj.12.15.1627.
  • Tillmann B, Krümpelmann S, Würthwein G, Wagner A, Schulze-Westhoff P, Hempel G, Jürgens H, Boos J. . „Pharmakokinetische Aspekte der oralen Applikation von Etoposid.“ Klinische Pädiatrie 210, Nr. 4: 159–164. doi: 10.1055/s-2008-1043872.
  • Rube C, Schuck A, Palkovic S, Hempel G, Hampel G, Boos J, Kohler A, Willich N. . ‘Phase-I trial of paclitaxel and concurrent radiotherapy in the treatment of malignant gliomas. Preliminary clinical and pharmacokinetical results.’ Strahlentherapie und Onkologie 174, Nr. SUPPL. 1: 2–5. doi: 10.1007/BF03038996.
  • Hempel G, Schulze-Westhoff P, Flege S, Laubrock N, Boos J. . ‘Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis.’ Electrophoresis 19, Nr. 16-17: 2939–2943. doi: 10.1002/elps.1150191624.
  • Hempel G, Karlsson MO, De Alwis DP, Toublanc N, McNay J, Schaefer HG. . ‘Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements.’ Clinical Pharmacology and Therapeutics 64, Nr. 6: 622–635. doi: 10.1016/S0009-9236(98)90053-4.

  • Hempel G, Haberland S, Schulze-Westhoff P, Möhling N, Blaschke G, Boos J. . ‘Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.’ Journal of Chromatography B: Biomedical applications 698, Nr. 1-2: 287–292. doi: 10.1016/S0378-4347(97)00299-5.
  • Hempel G, Krümpelmann S, May-Manke A, Hohenlöchter B, Blaschke G, Jürgens H, Boos J. . ‘Pharmacokinetics of trofosfamide and its dechloroethylated metabolites.’ Cancer Chemotherapy and Pharmacology 40, Nr. 1: 45–50. doi: 10.1007/s002800050623.
  • Wagner A, Hempel G, Boos J. . ‘Trofosfamide: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer.’ Anti-Cancer Drugs 8, Nr. 5: 419–431. doi: 10.1097/00001813-199706000-00002.

  • Hempel G, Lehmkuhl D, Krümpelmann S, Blaschke G, Boos J. . ‘Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography.’ Journal of Chromatography A 745, Nr. 1-2: 173–179. doi: 10.1016/0021-9673(96)00351-2.
  • Hempel G, Blaschke G. . ‘Direct determination of zolpidem and its main metabolites in urine using capillary electrophoresis with laser-induced fluorescence detection.’ Journal of Chromatography B: Biomedical applications 675, Nr. 1: 131–137. doi: 10.1016/0378-4347(95)00342-8.
  • Hempel G, Blaschke G. . ‘Enantioselective determination of zopiclone and its metabolites in urine by capillary electrophoresis.’ Journal of Chromatography B: Biomedical applications 675, Nr. 1: 139–146. doi: 10.1016/0378-4347(95)00348-7.
  • Lanvers C, Hempel G, Blaschke G, Boos J. . ‘Simultaneous determination of all-trans-, 13-cis- and 9-cis-retinoic acid, their 4-oxo metabolites and all-trans-retinol in human plasma by high-performance liquid chromatography.’ Journal of Chromatography B: Biomedical applications 685, Nr. 2: 233–240. doi: 10.1016/S0378-4347(96)00192-2.

  • Hempel G. . Anwendung der Kapillarelektrophorese und der HPLC zur Untersuchung des Metabolismus der Hypnotika Zopiclon und Zolpidem Dissertationsschrift, Universität Münster. Münster: Selbstverlag / Eigenverlag.

  • Blaschke G, Hempel G, Muller WE. . ‘Preparative and analytical separation of the zopiclone enantiomers and determination of their affinity to the benzodiazepine receptor binding site.’ Chirality 5, Nr. 6: 419–421. doi: 10.1002/chir.530050605.

Projekte

  • Erhöhung der Arzneimitteltherapiesicherheit durch digitales, interprofessionelles Medikationsmanagement - Digitales AMTS-Management ( – )
    Gefördertes Einzelprojekt: Viandar GmbH
  • Entwicklung eines Instruments zur Messung der Effektivität pharmazeutischer Interventionen in Altenheimen ( – )
    Gefördertes Einzelprojekt: Förderinitiative Pharmazeutische Betreuung e.V.
  • ADMET/PBPK Model development of sexual hormone to evaluate toxicokinetics of endocrine disruptor ( – )
    Gefördertes Einzelprojekt: Korea Institute of Science and Technology
  • Therapeutisches Drug Monitoring (TDM) von Antipsychotika und Antidepressiva mit getrockneten Kapillarblutproben im ambulanten Bereich ( – )
    Gefördertes Einzelprojekt: Apothekerstiftung Westfalen-Lippe
  • Bioanalytik eines FLT-3 Inhibitors ( – )
    Gefördertes Einzelprojekt: Bayerische Patentallianz GmbH
  • MAI-Score Evaluation im Rahmen des SiMbA-Projekts ( – )
    Gefördertes Einzelprojekt: Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung
  • Therapeutisches Drug Monitoring für Bewohner von Alten- und Pflegeheimen mit Hilfe der dried blood spot Methode ( – )
    Gefördertes Einzelprojekt: Dr. August und Dr. Anni Lesmüller-Stiftung
  • Überprüfung und Aktualisierung einer Liste von in Deutschland gesetzten Arzneistoffen mit Verdacht auf sensibilisierende und CMR-Eigenschaften ( – )
    Gefördertes Einzelprojekt: Berufsgenossenschaft für Gesundheitsdienst und Wohlfahrtspflege
  • InterAKT MAI Score Evaluation ( – )
    Gefördertes Einzelprojekt: Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung
  • Development and Evaluation of a Physiologically-Based Pharmacokinetic Model (PBPK) Population Model for pregnant Women ( – )
    Gefördertes Einzelprojekt: Bayer Technology Services GmbH
  • PopPK of Asparaginase: Reply to CHMP Follow-up II ( – )
    Gefördertes Einzelprojekt: medac Gesellschaft für klinische Spezialpräparate mbH
  • Einsatz von komplementärmedizinischen Arzneimitteln bei Patienten mit Krebserkrankungen ( – )
    Gefördertes Einzelprojekt: Apothekerstiftung Westfalen-Lippe
  • PopPk of Asparaginase: Re-Analysis of Pharmacokinetic Data ( – )
    Gefördertes Einzelprojekt: medac Gesellschaft für klinische Spezialpräparate mbH
  • Bioanalytics of Liposomal Doxorubicin ( – )
    Gefördertes Einzelprojekt: SocraTec R&D Concepts in Drug Research and Development GmbH
  • PopPk of Asparaginase: Reply to CHMP ( – )
    Gefördertes Einzelprojekt: medac Gesellschaft für klinische Spezialpräparate mbH
  • Apo-AMTS – Konzept zur Verbesserung der Arzneimitteltherapiesicherheit in der Apotheke ( – )
    Gefördertes Einzelprojekt: Apothekerkammer Westfalen-Lippe
  • Preclinical Pharmacokinetics of recombinant Asparaginase ( – )
    Gefördertes Einzelprojekt: medac Gesellschaft für klinische Spezialpräparate mbH
  • Anwendung und Optimierung des physiologisch-basierten pharmakokinetischen Modellings bei Kindern ( – )
    Eigenmittelprojekt
  • EPOC-MS-001-Doxo – European Paediatric Oncology Off-Patent Medicines Consortium Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours or leukaemia ( – )
    EU-Projekt koordiniert außerhalb der Universität Münster: EU FP 7 - Small or medium-scale focused research project | Förderkennzeichen: 222910
  • Populationskinetik von Asparaginase ( – )
    Gefördertes Einzelprojekt: medac Gesellschaft für klinische Spezialpräparate mbH
  • Schmerz – Schnelle Verfügbarkeit von Schmerzmitteln und anderen Betäubungsmitteln für Gäste von Hospizen ( – )
    Gefördertes Einzelprojekt: Landesinstitut für Gesundheit und Arbeit des Landes Nordrhein-Westfalen, Landeszentrum Gesundheit Nordrhein-Westfalen
  • Optimierung der Versorgung geriatrischer Bewohner von Alten- und Pflegeheimen durch intensive pharmazeutische Betreuung ( – )
    Gefördertes Einzelprojekt: Sonstige Mittelgeber
  • Populations-pharmakokinetischer Vergleich verschiedener Asparaginase-Formulierungen ( – )
    Gefördertes Einzelprojekt: Wirtschaft
  • Verbesserung der ambulanten Versorgung geriatrischer Patienten durch Pharmazeutische Betreuung ( – )
    Gefördertes Einzelprojekt: Stiftungen
  • Folate und deren Inhibitoren in der pädiatrischen Onkologie ( – )
    Eigenmittelprojekt
  • Optimierung der Pharmakotherapie bei geriatrischen Patienten durch Pharmazeutische Betreuung ( – )
    Gefördertes Einzelprojekt: Spender/Sponsoren